[New developments in cancer immunotherapy].
Recent progress unveiling the cellular and molecular basis of the immune response allows nowadays the design of novel therapies for tumor immunotherapy. These recent approaches translate into response rates that often surpass what can be obtained by conventional chemotherapies or targeted therapies. Here we present the main current developments with an accent on the Lausanne experience in the treatment of melanoma. First, the new developments of peptide-based vaccination are presented. Second, approaches related to adoptive transfer are illustrated with a particular attention for the patient conditioning using lymphodepletion. Finally, the Lausanne project of rational lymphocyte TCR optimization is described.
Michielin
O
O
Centre pluridisciplinaire d'oncologie, CHUV, Lausanne. Olivier.Michielin@unil.ch
Rufer
N
N
Romero
P
P
Laurent
J
J
Cerottini
J-P
JP
Gugisberg
D
D
Leyvraz
S
S
Speiser
D
D
D019496:Cancer Vaccines / Q000008:administration & dosage; D006801:Humans; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*
D019496:Cancer Vaccines